The clinical value of p21(WAF1/CIP1) expression in superficial bladder cancer

Nan-Haw Chow, Tzong Shin Tzai, Hong-Lin Cheng, Hsiao-Sheng Liu, Shih-Huang Chan, Yat-Ching Tong

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


The clinical value of p21(WAF1/CIP1) in superficial bladder cancer remains controversial. To address the question, we examined the expression patterns of p21 and p53 gene products and compared for their significance in a total of 89 cases of superficial (pTa/pT1) bladder cancer. Over-expression of p21 was detected in 32 of 89 (36%) tumors. But, the expression status did not correlate with biological indicators or clinical outcome (p > 0.1, respectively). Factors predicting clinical outcome were multiplicity for tumor recurrence (p = 0.0002) or patient survival (p = 0.03), and the histological grading for disease progression (p = 0.02) or patient survival (p = 0.05). Taking into account the p53 status, a trend approaching better prognosis for p53+p21+ tumors was observed compared with that of p53+p21- bladder cancer (p = 0.08). Our data indicate that evaluation of p21 status does not provide better prognostic information compared with conventional biological indicators of superficial bladder cancer. Maintenance of p21 appears to abrogate the deleterious effects of p53 alterations in the tumorigenesis of human bladder.

Original languageEnglish
Pages (from-to)1173-1176
Number of pages4
JournalAnticancer Research
Issue number2 B
Publication statusPublished - 2000 Jan 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'The clinical value of p21(WAF1/CIP1) expression in superficial bladder cancer'. Together they form a unique fingerprint.

Cite this